INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.3400
-0.0600 (-15.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.4000
Open0.4000
Bid0.2888 x 1100
Ask0.4000 x 1200
Day's Range0.3150 - 0.4299
52 Week Range0.1400 - 11.6500
Volume8,410,627
Avg. Volume3,580,098
Market Cap25.813M
Beta (3Y Monthly)4.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire5 days ago

    INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions

    INSYS Therapeutics, Inc. (INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June 11, 2019 INSYS received interim approvals from the U.S. Bankruptcy Court for the District of Delaware for its First Day motions related to the Chapter 11 petitions filed on June 10, 2019. Andrew G. Long, Chief Executive Officer of INSYS Therapeutics, Inc., said, “This is an important step forward in our court-supervised process, which is intended to fairly and transparently address the Company’s legacy legal liabilities. The Court granted INSYS interim approval to continue its existing cash management system to collect and disburse cash generated by the business.

  • GlobeNewswire7 days ago

    INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities

    INSYS Therapeutics, Inc. (INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced today that INSYS has filed voluntary cases (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court in the District of Delaware (the “Court”) to facilitate the sale of substantially all of the Company’s assets and address the Company’s legacy legal liabilities. INSYS intends to continue operating its business in the ordinary course while it pursues these transactions through the court-supervised sale process.

  • GlobeNewswirelast month

    INSYS Therapeutics Reports First Quarter 2019 Results

    Company Continues to Execute Against Pipeline-Focused StrategyNew Drug Application Submitted for Proprietary Naloxone Nasal Spray FormulationCompany Provides Liquidity Update.

  • GlobeNewswire2 months ago

    INSYS Therapeutics Implements Leadership Changes

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the INSYS Board of Directors to resign as President and CEO of the Company. In connection with INSYS’ leadership changes, Andrece Housley, INSYS’ Corporate Controller, has been appointed Chief Financial Officer, succeeding Mr. Long.

  • GlobeNewswire3 months ago

    INSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Drug Dependence Annual Scientific Meeting

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the Company will present a poster of its pharmacokinetic (PK) study of its novel naloxone nasal spray versus intravenous and intramuscular injection at the College on Problems of Drug Dependence (CPDD)’s 81st Annual Scientific Meeting in San Antonio, Texas on Monday, June 17, 2019 at 8:00am Central Time. A copy of the poster will be made available on the Company’s website following the presentation. INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life.

  • GlobeNewswire3 months ago

    INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results

    PHOENIX, March 07, 2019 -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray.

  • GlobeNewswire3 months ago

    INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7

    PHOENIX, March 06, 2019 -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray.

  • ACCESSWIRE3 months ago

    Non-Opioid Treatment Cos. for Investors in Wake of Purdue Pharma News

    HENDERSON, NV / ACCESSWIRE / March 6, 2019 / OxyContin maker Purdue Pharma is exploring filing for bankruptcy as one of its options to address potentially significant liabilities from thousands of lawsuits ...

  • ACCESSWIRE4 months ago

    Four Marijuana Stocks Seeing New Highs On Wednesday

    CORAL GABLES, FL / ACCESSWIRE / February 27, 2019 / The marijuana stock market has come quite a long way over the course of the past few years. Generations upon generations have disregarded cannabis and ...

  • ACCESSWIRE4 months ago

    Watch These 4 Marijuana Stocks On Monday (2/25/19)

    CORAL GABLES, FL / ACCESSWIRE / February 25, 2019 / Perhaps what is most interest about marijuana stocks is how, despite years of condemnation and uncertainty, companies invested in the cannabis sector ...

  • GlobeNewswire4 months ago

    INSYS Therapeutics Presented Poster of Initial Pharmacokinetic Study of Epinephrine Nasal Spray for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis at American Academy of Allergy, Asthma and Immunology Annual Meeting

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, presented a poster of its initial pharmacokinetic (PK) study of comparative bioavailability of epinephrine nasal spray and EpiPen® in adults with seasonal allergies at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Francisco, California on Feb. 24, 2019. The results presented at the meeting were from the initial PK study with a total of 60 adults with seasonal allergies.

  • ACCESSWIRE4 months ago

    Four Marijuana Stocks Looking To Raise The Bar On Wednesday (2/20/19)

    CORAL GABLES, FL / ACCESSWIRE / February 20, 2019 / The marijuana stock market has managed to attract momentous investor attention over the last couple of years as companies in the industry have capitalized on the recent shift in public opinion. As the future of the industry pushes on, Integrated Cannabis Solutions Inc (IGPK), Trulieve Cannabis Corp (OTC PINK: TCNNF), OrganiGram Holdings Inc (OGRMF) (OGI.V) and Insys Therapeutics Inc (INSY) are four pot stocks gaining tread this week. Integrated Cannabis Solutions Inc (IGPK) is actively engaged in evaluating investment opportunities in early stage ventures at the crossroads of the rapidly growing medical and recreational marijuana industry.

  • ACCESSWIRE4 months ago

    4 Marijuana Stocks Gaining Speed On Tuesday (2/19/19)

    Although cannabis remains federally criminalized, if more US states follow in California's footsteps, this may result in an influx of investors looking to the marijuana stock market for opportunities. Nabis Holdings (INNPF) (NAB), INSYS Therapeutics Inc (INSY), CannTrust Holdings Inc (OTC PINK: CNTTF), and Canopy Rivers Inc (OTC PINK: CNPOF) (RIV.V) are four cannabis companies picking up speed on Tuesday. Nabis Holdings (INNPF) (NAB) is a Canadian investment company focused on investing in high-quality cash flowing and strategic assets across multiple aspects of the cannabis sector primarily in the U.S. limited license states with a roadmap to expand globally.

  • ACCESSWIRE4 months ago

    4 Marijuana Stocks Looking To Pick Up Speed This Month

    CORAL GABLES, FL / ACCESSWIRE / February 8, 2019 / Marijuana stocks have become one of the hottest topics in the news over the course of the past few years. Recently, the cannabis industry has seen an increase in capital enjoyed by companies working to optimize and innovate products for the adult-use recreational cannabis market. As it relates to positive legislation brought forth by lawmakers, as many as 33 states in the U.S. have passed laws allowing for the use of cannabis, with many of those offering recreational cannabis as well.

  • ACCESSWIRE4 months ago

    Cannabis Plays Going Higher

    HENDERSON, NV / ACCESSWIRE / February 7, 2019 / January was a historic month for marijuana stocks. Almost all cannabis stocks reported gains last month and the top performers reported gains between 80%-90%. ...

  • ACCESSWIRE4 months ago

    4 Marijuana Stocks Looking to Set the Standard

    As we see what February has in store, Leafbuyer Technologies Inc (OTC:LBUY), MariMed Inc (MRMD), Tilray Inc (TLRY), and INSYS Therapeutics (INSY) are 4 pot stocks worth looking into on Tuesday. Leafbuyer Technologies Inc (OTC:LBUY) is one of the leading online resources for those in the cannabis industry. The Company, through its subsidiary, LB Media Group LLC, operates an online platform for trending cannabis deals and specials and has been lauded as the most comprehensive source for ascertaining cannabis-related information.

  • ACCESSWIRE4 months ago

    Playing the Big Cannabis Rebound

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Cannabis stocks, as measured by the Global Cannabis Stock Index, bounced back from Q4 losses of 44.2%, rallying 44.2% in January, the second-best month in ...

  • ACCESSWIRE4 months ago

    Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Some consider the small-cap and mid-cap - ''smid-cap'' - zone with market caps of $5 billion or less, a bit risky. They aren't wrong. However, if you can ...

  • ACCESSWIRE5 months ago

    Biotechs You Need to Radar Now

    HENDERSON, NV / ACCESSWIRE / January 30, 2019 / The biotechnology sector has been roaring back strong in 2019. There a few companies that we think you should be researching right now. One company who's ...

  • ACCESSWIRE5 months ago

    Biotech Stocks to Watch this Week

    HENDERSON, NV / ACCESSWIRE / January 28, 2019 / Biotech can be a lucrative sector for investors. Companies in the industry are often working toward well-defined goals such as clinical trial results, which ...

  • GlobeNewswire5 months ago

    INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the results of a dose-finding pharmacokinetic (PK) study (INS015-18-124) of its epinephrine nasal spray.

  • GlobeNewswire5 months ago

    INSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

    PHOENIX, Jan. 03, 2019 -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray.

  • ACCESSWIRE6 months ago

    Cannabis Firms Set to Explode

    HENDERSON, NV / ACCESSWIRE / December 31, 2018 / The market is rallying, and cannabis stocks are ready to rally as well. The companies below could lead the charge heading into 2019. An extremely interesting ...

  • GlobeNewswire6 months ago

    INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that Dr. Dean Mariano, senior director, clinical development and medical affairs at INSYS, presented during the first day of the U.S. Food and Drug Administration’s (FDA) Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee meeting being held Dec. 17 and 18, 2018.

  • GlobeNewswire6 months ago

    INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today provided an update on its product pipeline, which includes cannabidiol (CBD) oral solution as well as epinephrine and naloxone nasal sprays. “Our strategic shift in focus away from opioids and to pharmaceutical-grade cannabinoids and novel drug delivery systems continues to gain momentum and has been driven by our strong commitment to advancing our diverse product pipeline,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.